Antares Pharma, Inc.
Price (11/17/05): $1.16
Avg Vol (3 month): 175,474
Mkt Cap: $48.7MM
52-Week Change: (4.76%)
Cash & STI (9/30/05): $3.62MM
52-Week High (12/30/04): $1.61
Enterprise Value: $43.03MM
52-Week Low (5/25/05): $0.70
Price/Sales (ttm): 20.15x
Return on Assets (ttm): (45.69%)
Price/Book (mrq): 12.39x
Return on Equity (ttm): (118.97%)
Antares Pharma, Inc. operates as a specialty drug delivery/pharmaceutical company providing
drug delivery systems for pharmaceuticals. The company’s technology platforms include
transdermal gels, fast-melt oral tablets, disposable minineedle injection systems, and reusable
needle-free injection systems. Its transdermal drug delivery platform develops gels, which
deliver medication with less potential for skin irritation, and avoiding the initial gastrointestinal
and liver uptake problems of some orally ingested drugs. The company’s fast-melt oral
disintegrating tablets are designed to help patients experiencing difficulty in swallowing pills,
tablets, or capsules. Its injection device platform features reusable needle-free injectors, which
deliver precise medication doses through pressurized liquid penetration of the skin without a
needle; disposable minineedle injectors, which are designed to provide subcutaneous injection
capabilities with reduced discomfort and safety of a shielded needle; and emerging vaccine
intradermal injectors. The company was incorporated in 1979 and was formerly known as
Medi-Ject Corporation. Antares Pharma is headquartered in Exton, Pennsylvania.
We are initiating coverage on Antares Pharma, Inc. We believe the company has
many catalysts both short and long term which could provide shareholders
significant upside from current levels.
Antares product portfolio features development-stage products as well as
approved products which are marketed and sold in over 38 countries.
The Medi-Ject VISION® needle-free injector system i